Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE™-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a fourth $50 million milestone payment obligation from Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, worldwide collaborator on ibrutinib in oncology.

This trial is a randomized, multicenter, open-label Phase III study of ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in patients 65 years or older with treatment-naïve CLL/SLL. The study design is in accord with a Special Protocol Assessment (SPA). The study is designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival (PFS); the comparator is single agent chlorambucil. This global study is planned to enroll 272 patients worldwide.

Further information about this trial can be found at www.clinicaltrials.gov:
NCT01722487 – "A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)."

About the Janssen Collaboration
As previously announced on December 8, 2011, Pharmacyclics entered into a worldwide collaboration with Janssen to develop and commercialize ibrutinib, a novel, oral, first-in-class Bruton's Tyrosine Kinase (BTK) inhibitor. Pharmacyclics received from Janssen an upfront payment totaling $150 million upon signing the contr
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Md. , Aug. 27, 2015  BioElectronics Corporation (OTC ... announced today that three abstracts featuring the use of ... at the 9 th Congress of the European ... 2-5 th September 2015. The Company will also ... Dr Gianluca Bagnato , department clinical and ...
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
(Date:8/27/2015)... , Aug. 27, 2015   Americord Registry ... tissue , and placenta tissue banking company, ... blood banking e-commerce website. This new website makes the ... with an interactive shopping cart and checkout process. ... "Most cord blood banking websites make this service difficult ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
(Date:8/28/2015)... ... August 28, 2015 , ... The Louis W. Sullivan ... innovation to transform quality and efficiency of healthcare delivery worldwide, announced the release ... aggregated before being publicly shared to document progress and inform policy in a ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ECP or ... selling External Counterpulsation (EECP or ECP) machines with a full clinic licence to help ... business since 2007 helping people prevent and reverse heart disease through its ...
(Date:8/28/2015)... ... 28, 2015 , ... Super-Sod launched their new website this summer. ... notable change is the responsive web design. Website users will now have an improved ... quote requests for sod, sign-up for the monthly turf-tips email, and find a local ...
(Date:8/28/2015)... ... , ... On October 3, 2015, BethAnn Telford of TeamBT and Maria Parker of ... a shared mission: to beat brain cancer. In one grueling day, they will race ... to the South Rim over 21.1 miles and more than 10,000 feet of elevation change. ...
(Date:8/27/2015)... ... ... Keck Graduate Institute (KGI), School of Pharmacy celebrated its Second Annual White Coat ... them as members of the 2nd class of the KGI School of Pharmacy and ... service and patient care, the White Coat Ceremony is held every year when new ...
Breaking Medicine News(10 mins):Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Women Athletes Cross the Grand Canyon to Raise Funds for Brain Cancer Research – October 3rd 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4
... chances of recurrence, death higher than among normal-weight patients ... survivors who are moderately or severely obese face tougher ... a new study reveals. , The finding builds on ... risk for developing colon cancer in the first place. ...
... ... and Summarized Demographic Reporting increases value of Intellimed,s Reporting Tool. , ... Phoenix, Ariz. (PRWEB) March 9, 2010 ... new enhancements to it’s popular medical reporting software system Intellimed Intelligent Client (IM-IC)., , ...
... ... ... ... ...
... ... ... ... ...
... papers, reviews, case reports, editorials and letters ... a wide range of related sciences. ... of radiopharmaceuticals, nuclear and molecular imaging analysis, ... and radionuclide therapy. June-Key Chung, MD, ...
... ... one of America,s Top Ophthalmologist , ... (Vocus) March 9, 2010 -- Khanna Institute of LASIK and ... has been selected as one of the America’s Top Ophthalmologist. Ophthalmologists are eye MD’s. ...
Cached Medicine News:Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 3Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 4Health News:Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update 2Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 2Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 3Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 4Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 5Health News:Aspen Dental Announces Opening of First Practice In Nebraska 2Health News:Aspen Dental Announces Opening of First Practice In Nebraska 3Health News:Aspen Dental Announces Opening of First Practice In Nebraska 4Health News:Aspen Dental Announces Opening of First Practice In Nebraska 5Health News:Aspen Dental Announces Opening of First Practice In Nebraska 6Health News:Aspen Dental Announces Opening of First Practice In Nebraska 7Health News:Rajesh Khanna, MD Selected as One of America's Top Ophthalmologist 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: